Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Publication
Article
AJPB® Translating Evidence-Based Research Into Value-Based Decisions®
Specialty PharmacyVolume5 Issue 6
Comparative Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients
Author(s):
Among rheumatoid arthritis patients newly treated with adalimumab, etanercept, or infliximab, lower dose escalation rates and costs were seen with etanercept.
This study supports earlier research on the comparative effectiveness of tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients, but is unique in utilizing both clinical outcomes data from US clinical practices and actual drug utilization data from claims.
- Increased costs resulting from TNF blocker dose escalation may not always be accompanied by an improvement in clinical benefit.
- In the current comparative effectiveness research paradigm, understanding the clinical benefit gained from additional cost is critical to payers.
- Among RA patients newly treated with adalimumab, etanercept, or infliximab, lower dose escalation rates and costs were seen with etanercept.
Articles in this issue
Practice Economics and the Decision to Prescribe Oral Oncolytics
Specialty Pharmacy Improves Adherence to Imatinib
Comparative Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients
The Role of Specialty Drugs in Private Sector Healthcare Spending
Genetic Testing: Front and Center
A Medical Director Perspective on Specialty Pharmacy
Related Content
